A Project Report on,

Lincoln Pharmaceuticals Ltd.

Towards partial fulfillment of the requirement of
the BACHELOR OF BUSINESS
ADMINISTRATION Programme of Gujarat
University.

Submitted to:- Professor Parin Shah of

Som-Lalit Institute of BusinessAdministration,
(affiliated to Gujarat University).

Guided by:- Prof Parin Shah

Submitted By:- Rawal Dhwani Hastimal

Roll number:- 42
Division:- A

I
 CERTIFICATE

I, Dhwani Rawal , hereby certify that the work which is being

presented in this Project Report in partial fulfillment of the
requirements of BBA Programme and submitted to Som-Lalit
Institute of Business Administration is an authentic record of my own
work carried out during fourth semester. The matter presented in
this Project Report has not been submitted by me for the award of
any other degree elsewhere.

Place: AHMEDABAD
Date: 21 March,2022 Signature

PROJECT INCHARGE PRINCIPAL

II
 PREFACE

As BBA studentsour aim should not be only to learn theoretical concepts in the
classroom, but it becomes more important as how we apply those concepts in
practices. In present scenario the world is developing so fast, and thus the
technological and application theory is changing at a greater phase. The study
inculcates students to think out of the box. We come across many modern
theories and implementation of machineries, to start new business or
improving working of a present organisation. We must have the knowledge of
both theory and practical, through it, the student can know about how to
apply their mind in the real business world.

The vary purpose of industrial visit is to create awareness about the industrial
environment among the students. The importance of industrial visit and
project preparation has been widely accepted in the education institutions.
Thus knowing the importance of such practical visit, our college is providing
with such a programme to enhance the overall development of the students.
Lincoln Pharmaceuticals Ltd. gave me the golden opportunity to carry out my
visit in such a great organization. I have prepared the detail report on this visit.
I have tried my best to collect all necessary information relating to the project
work.

III
 ACKNOWLEDGEMENT

This project is done as a semester project, as a part of Gujarat University BBA

programme. I am really thankful to my instructor Prof Parin Shah, Som-Lalit
Institute of Business Administration, Ahmedabad, for his valuable guidance and
assistance, without which the accomplishment of the task would have never
been possible. I am also thankful to him for giving this opportunity to explore
into the real world and realize the interrelation of business and economics,
without which a society can never progress.

Without the help of managers at Lincoln Pharmaceuticals Ltd. this Industrial

Tour would not have been a learning experience. Finally I would like to thank
out college and our principal Prof Shri K J Patel whose constant efforts are
helping us all grow.

IV
Contents
INTRODUCTION OF INDUSTRY...............................................................................................................1
COMPANY PROFILE................................................................................................................................4
HUMAN RESOURCE DEPARTMENT......................................................................................................11
PRODUCTION DEPARTMENT...............................................................................................................12
MARKETING DEPARTMENT..................................................................................................................20
FINANCING DEPARTMENT...................................................................................................................23
CORPORATE SOCIAL RESPONSIBILITY..................................................................................................27
PORTER’S FIVE FORCE ANALYSIS..........................................................................................................32
COMPETITION ANALYSIS.....................................................................................................................34
SWOT ANALYSIS...................................................................................................................................37
SUGGESTIONS......................................................................................................................................43
BIBLIOGRAPHY.....................................................................................................................................45

V
 INTRODUCTION OF INDUSTRY

India is the largest provider of generic drugs globally. Indian pharmaceutical

sector supplies over 50% of the global demand for various vaccines, 40% of the
generic demand for US and 25% of all medicines for UK. India contributes the
second-largest share of pharmaceutical and biotech workforce in the world.
According to the Indian Economic Survey 2021, the domestic market is
expected to grow 3x in the next decade. India’s domestic pharmaceutical
market is estimated at US$ 42 billion in 2021 and likely to reach US$ 65 billion
by 2024 and further expand to reach US$ 120-130 billion by 2030. According to
India Ratings & Research, the Indian pharmaceutical market revenue is
expected to be over 12% Y-o-Y in FY22.

Globally, India ranks 3rd in terms of pharmaceutical production by volume and

14th by value. The domestic pharmaceutical industry includes a network of
3,000 drug companies and 10,500 manufacturing units.

In the global pharmaceuticals sector, India is a significant and rising player.

India is the world's largest supplier of generic medications, accounting for 20%
of the worldwide supply by volume and supplying about 60% of the global
vaccination demand.

India is the 12th largest exporter of medical goods in the world. The country’s
pharmaceutical sector contributes 6.6% to the total merchandise exports. As of
May 2021, India supplied a total of 586.4 lakh COVID-19 vaccines, comprising
grants (81.3 lakh), commercial exports (339.7 lakh) and exports under the
COVAX platform (165.5 lakh), to 71 countries.

1
As of August 2021, CARE Ratings expect India's pharmaceutical business to
develop at an annual rate of 11% over the next two years, to reach more than
US$ 60 billion in value.

Indian drugs are exported to more than 200 countries in the world, with US
being the key market. Generic drugs account for 20% of the global export in
terms of volume, making the country the largest provider of generic medicines
globally. It is expected to expand even further in the coming years. The Indian
pharmaceutical exports, including bulk drugs, intermediates, drug
formulations, biologicals, Ayush & herbal products and surgical, reached US$
24.44 billion in FY21. Indian drugs and pharmaceuticals exports reached US$
5.78 billion between April 2021 and June 2021.

India’s medical devices market stood at US$ 10.36 billion in FY20. The market is
expected to increase at a CAGR of 37% from 2020 to 2025 to reach US$ 50
billion.

‘Pharma Vision 2020’ by the Government’s Department of Pharmaceuticals

aims to make India a major hub for end-to-end drug discovery. The Indian
drugs and pharmaceuticals sector received cumulative FDIs worth US$ 18.12
billion between April 2000 and June 2021. The foreign direct investment (FDI)
inflows in the Indian drugs and pharmaceuticals sector reached US$130 million
between April 2021 and June 2021. In FY21, North America was the largest
market for India’s pharma exports with a 34% share and exports to the U.S.,
Canada and Mexico recorded a growth of 12.6%, 30% and 21.4%,
respectively.To achieve self-reliance and minimise import dependency in the
country's essential bulk drugs, the Department of Pharmaceuticals initiated a
PLI scheme to promote domestic manufacturing by setting up greenfield plants
with minimum domestic value addition in four separate ‘Target Segments’ with
a cumulative outlay of Rs. 6,940 crore (US$ 951.27 million) from FY21 to FY30.
In June 2021, Finance Minister Ms. Nirmala Sitharaman announced an
additional outlay of Rs. 197,000 crore (US $26,578.3 million) that will be

2
utilised over five years for the pharmaceutical PLI scheme in 13 key sectors
such as active pharmaceutical ingredients, drug intermediaries and key starting
materials.

Under Union Budget 2021-22, the Ministry of Health and Family Welfare has
been allocated Rs. 73,932 crore (US$ 10.35 billion) and the Department of
Health Research has been allocated Rs. 2,663 crore (US$ 365.68 billion). The
government allocated Rs. 37,130 crore (US$ 5.10 billion) to the 'National
Health Mission’. PM Aatmanirbhar Swasth Bharat Yojana was allocated
Rs.64,180 crore (US$ 8.80 billion) over six years. The Ministry of AYUSH was
allocated Rs. 2,970 crore (US$ 407.84 million), up from Rs. 2,122 crore (US$
291.39 million).

India plans to set up a nearly Rs. 1 lakh crore (US$ 1.3 billion) fund to provide
boost to companies to manufacture pharmaceutical ingredients domestically
by 2023.

In August 2021, Union Health Minister, Mr. Mansukh Mandaviya announced

that an additional number of pharmaceutical companies in India are expected
to commence manufacturing of anti-coronavirus vaccines by October-
November 2021. This move is expected to further boost the vaccination drive
across the country.

In July 2021, Delhi Pharmaceutical Sciences and Research University (DPSRU)

collaborated with All India Institute of Ayurveda (AIIA) to focus on assessment
of application of ayurvedic and medicinal plant-based drugs in modern
medicines.

India is the largest producer of vaccines worldwide, accounting for 60% of the
total vaccines, as of 2021.

3
 COMPANY PROFILE

The Company was incorporated as a public limited company by

converting partnership concern M/s. Lincoln Pharmaceuticals under
Part 9 of the Companies Act 1956. M/s. The Corporate office and the
Register office of the company is located at Satyam Complex, Lincoln
House, B/H, Science City Road, Sola, Ahmedabad, India. The plant of
the company is at 10 12 13, Trimul Estate, Khatraj, Kalol Taluka,
Gandhinagar, India.

Lincoln Pharmaceuticals was established as a partnership firm on

18th January 1979 with Mr. Rajni G. Patel, Mr. Hasmukhbhai I.Patel,
Mrs. Hansaben A.Patel, Mrs. Jivtiben C.Patel, Mrs. Jiviben T.Patel and
Mrs. Lilaben T. Patel as partners, with its main object of
manufacturing pharmaceutical formulations.

The business was started in Naroda G.I.D.C estate. Further on 9

December 1981, Mr.Mihir V. Patel, Mr.Maheshbhai M.Patel,
Mr.Yogeshkumar I. Patel and Mrs.Madhuben V.Patel were admitted
as Partners. The firm was carrying on its business by getting its
products manufactured on Loan and Licence Basis from 1979 to
1982.

All the partners decided and agreed vide resolution dated 30

December 1984 that all members of Co-partnership should register
the said firm as Public Limited Company for sake of smooth working,
better and effective management and improvement and

4
advancement of business. It was also decided as per the said
resolution that such company should carry out and continue the
existing business of the firm. As a result, an the incorporation of the
Company on 20th January 1995, all the properties of the firm
(movable & immovable) and all the liabilities of the firm 1955 an the
closing of the business of the day proceeding the date of
incorporation of the Company vested in the Company. Since, date of
incorporation of the Company i.e, 20th January 1995, all the assets
and liabilities, aforesaid as on 19th January 1995, vested in the
Company. Company is carrying on running business of erstwhile M/s.
Lincoln Pharmaceuticals having its formulations production facilities
at Naroda, GIDC, Ahmedabad, Gujarat, of manufacturing tablets,
capsules, liquid and powder syrups and ointments. Company is also
getting its products manufactured on "Loan and License" basis from
other manufacturers to meet the demand of small volume
parenterals. The company came out with a Public Issue in February
1996 to part-finance its project. In 2000-01 thecompny has been
graned ISO 9002 certificte and WO registration.

The Company has now decided to establish modern formulations

manufacturing plant at Village: Khatraj. Tal:Kalol, Olaf. Mehsana in
Gujarat to manufacture small volume parenterals like Dry powder
injectables, liquid vial, liquid ampoules and eye drops and expand its
production capacities of manufacturing tablets, capsules,
liquid/powder syrups and ointment and also to establish fully
equipped laboratory to undertake in house testing of its products for
better quality control and give thrust on Research and Development.
Company has already acquired non agricultural land Admeasuring:
8833 Sq. Mtrs. and is in the process of acquiring further land adm.
Approximately 11,170 Sq.Mtrs. Company has given advance for
booking cement and steel and are preparing to commence
5
construction of factory building at new site. Company has identified
all plant and machineries and has also given advance to major plant
& machinery suppliers far those machineries which has longer
delivery period, so as to implement the project an time. The
company has existing manufacturing facilities at Naroda and if is
already selling its products all over India and is having thrust in the
markets of Gujarat, Rajasthan, Andhra Pradesh, Bihar and Jammu.

2000 - The company has signed agreements with NSDL & CDSL for
dematerialisation.

2003 - The Joint Director of General Government of India has given

the certificate of recognition of Export House to the company.

-Lincoln Pharmaceuticals introduces AIDS Drugs .

-Launched US FDA approved drug Gatifloxacin.

-Launched PROLIN - NATURAL .

-Lincoln Pharmaceuticals Ltd has informed that it has launched a

new drug under the brand name of 'Namsafe'.

- Lincoln Pharmaceuticals Ltd has delists equity shares from Delhi

Stock Exchange Association Ltd .

2005 -Lincoln Pharmaceuticals secures export order from England,

UK .

2006 -Lincoln Pharma introduces Nozzled Liquid formulations .

-Lincoln Pharmaceuticals secures order from Republic Democratic of

Congo .

-Lincoln Pharmaceuticals introduces Vivian Roll On in Novel Drug

Delivery System.

6
-The Company has signed agreement with Russian firm M/s. Fortune
Impex Ltd for marketing Company's manufactured products in
Russia.

-Company has splits its Face value of Shares from Rs 10 to Rs 2

2007 -Lincoln Pharmaceuticals recommends final Dividend @ 12%

2008 .

-Lincoln Pharmaceuticals recommends final Dividend @ 12% 2009 .

-Lincoln Pharmaceuticals has incorporated new Company namely

M/s. Zullinc Healthcare Ltd as wholly owned subsidiary Company of
Lincoln Pharmaceuticals Ltd. .

-Company has Consolidates its Face value of Shares from Rs 2 to Rs

10

2010 -Lincoln Pharmaceuticals Ltd. gains market share with

technologically advanced Collagen Bio-tech products .

2011 -Lincoln Pharmaceuticals wins patent for a Novel Nasal Drug

delivery system introduces India's first Nasal Spray treatment for
Vomiting.

-Lincoln Pharmaceuticals Ltd. introduces India's first Long-Acting

Paracetamol 'Pa-12' for Long term relief from Fever and Pain .

-Lincoln Pharmaceuticals Ltd launches Antimalarial drug 'ARH 1'

developed with innovative dose optimization technology, for the first
time in the world.

-Lincoln Pharmaceuticals Ltd. launches Ayurvedic Product 'ISL

Granules' to serve mother and child healthcare segment.

-Lincoln Pharmaceuticals has acquired / purchased 62 Lacs equity

shares of M/s. Lincoln Parenteral Ltd and by virtue of said acquisition

7
/ purchase of equity share, M/s. Lincoln Parenteral Ltd has become
subsidiary Company

2012 -Lincoln Pharmaceuticals has recommended the payment of

Dividend @ Rs. 0.60/- per equity share (6%) on face value of Rs. 10/-
each

2013 -Lincoln Pharmaceuticals has recommended the payment of

Dividend of Rs. 0.60 (@ 6%) per equity share of face value Rs. 10/-
each.

2014 -"Lincoln Pharmaceuticals Ltd has launched an Ultramodern

State of Art plant for Injectable".

-Company has commended the payment of Dividend of Rs. 0.60/- per

equity share (@ 6%) of face value of Rs. 10/- each of the Company.

2015 -The company has successfully launched a cough syrup called

Namcold DX which contains Dextromethorphan Polistrirex.

2016 -"Lincoln Pharmaceuticals launches Vaginal Spray for "FIRST

TIME IN INDIA".

2017-18 –Launched next generation progesterone therapy

“ProlinSpray”.

2018-19 – 1MW Solar Roof installed.

-Targeting regulated market inspection.

2019-20 –Recived EU GMP.

-Patent for Diclofenac Rectal pray.

2020-21 –Debt free company.

-Launched Vitamin C+ Zinc.

8
Lincoln Pharmaceuticals shares its presence with fellow foremost top notch
excellence driven pharmaceutical producers, engaged in manufacturing and
marketing several therapeutic molecules under WHO-GMP guidelines. What
makes Lincoln stands apart is their commitment to deliver unsurpassed quality
of innovative products for the betterment of human health. Their drugs are
developed using best in class guidelines and all that at a very cost-effective
rates.

Mission

Through optimal and continual practices, Lincoln Pharmaceuticals dreams

towards transform its mission into actuality.

1. To lend assistance to the healthcare industry in their virtuous cause of

healing the people through reasonably priced solutions.

2. To create “Healthcare for All” an actuality by modest participation of

premium however low-cost pharma products

Vision

To spark a universal attempt to uncover cures of diseases by focused and

targeted R&D, through forging congenial alliances both domestically and
internationally.

Corporate Profile

The overall carpet area of the plant spreads to 3750 sq.m. which is further
segregated into various divisions for tablet and capsule manufacturing
facilities. All divisions possess appropriate room for existing operations and
arrangements for potential future development.

9
Operated by professionals, these stores are managed with absolute perfection.
Non-Beta Lactam production plant is located at Khatraj. Anti-tuberculars
(specifically Rifampicin), have a separate area there. Known for being a
employee focused Company, Lincoln Pharma places utmost focus on personal
development of human skills, marketing techniques, and safety standards for
its work force. The organization is dedicated to its moral obligations towards
the environment, share holder family and community as whole.

The seeds of innovation which were sprinkled in the year 1979, rose out of the
earth and grew up into a blooming flower which has been spreading its
fragrance till date.

Milestones

1979 - Started Lincoln Pharma in the year of 1979.

1984-85 – We got WHO – GMP for our plant/production unit.

1990 - Globle development – STARTED EXPORT TO Tanzania AND Mauritius –

1990.

1995-96 - Orgnaization turn up to Public Limited company from Partnership.

1997-98 - Domestic Network across nation , we started the Ethical domestic

marketing – All India level.

2000 - Marketing Strength we have covered 80% of all India Market with 400
field staff and today we are having filed strength of 600 to 625.

2001 - Own Research & Development – R&D Center started in the year of 2001
Export house certificate received in the year of.

2010 - Specialty and patented product – we have developed 3 NDDS products

and launched the product in 2011 (Pa-12, VIVIAN 1 ML, ARH 1 ML) .

10
Lincoln’s Khatraj manufacturing facilities fulfills the cGMP guidelines and
abides with WHO, cGMP norms.

Regulatory Approvals :

The Finished Dose Formulation facility at Khatraj, Gujarat (India) serves

towards ever-increasing need for exports of branded generic products.
Following regulatory authorities have certified and accredited the facility:

-MCAZ (Zimbabwe)

-NDA (Uganda)

-TFDA (Tanzania)

-NAFDAC (Nigeria)

-PPB (Kenya)

-FDB (Ghana)

-PMPB Malawi

-Ethopia.

11
 HUMAN RESOURCE DEPARTMENT

Lincoln Pharmaceuticals has 398+ employees in their company. Mrs. Sani Soni
and Mr. Vishal Mehta are an Assistant Manager of Human Resource
department following them Mrs. Neha Ravani is a Senior Human Resource
Executive and Mrs. Rushi Trivedi is a Human Resource Officer.

Professional, motivated and highly qualified personnel are among Mitsu’s most
precious assets and the key to our future growth. The Company encourages its
employees to perform to their best ability and supports open collaboration,
engagement and involvement. Constant improvements are brought about in
work practices, technological and technical developments, and productivity of
employees through training and learning development programmes. The
Company believes in offering the best possible opportunities to its human
resource for growth, development and a better quality of life, while developing
their potential and maximising their productivity. Further, the Company also
believes in talent acquisition to augment its plan of making its presence firm in
the market its leads. As at March 31, 2020 the Company strength stands at
288.

The management believes that competent and committed human resources

are vitally important to attain success in the organization. In line with this
philosophy, utmost care is being exercised to attract quality resources and
suitable training is imparted on various skillsets and behavior. It is always
proactive with respect to the human resource development activities. A
significant effort has also been undertaken to develop leadership as well as
technical / functional capabilities in order to meet future talent requirement.

12
 PRODUCTION DEPARTMENT

The latest top notch, completely computerized facility is situated in

Ahmedabad close to Khatraj having all the resources to manufacture and
export pharmaceuticals. Products that the pharma manufacturing unit
produces are tablets, capsules, injections, liquid and dry syrups (dry powder).
The new factory includes completely computerized method for production
with online controls and inventory. They even additionally own extremely
competent and qualified workforce for production management.

The compny agree to required emphasis on quality control and carry

appropriate safeguards to assure there aren’t any lapses on the production
front.

Lincoln Pharma offers contract manufacturing facilities for verticals like

pharmaceuticals, food supplements, nutraceuticals, and vitamins. This contract
manufacturing facilities were evolved prior to fixed up the agreement as per
the best practice of industries and ensures that it is in compliance with “GMP
Requirement”.

They can easily assist their clients in preparations when customized

formulation can be developed within their Research and Development facility
from lab scale to pilot batches.

Quality is the core of the development process. The management ensures that
all the products are of unsurpassed quality and properly tested by the internal
CORPORATE QUALITY ASSURANCE department. With right balance of
innovation and quality the Company ensure that the products that reach out to
end consumers are quite up to the mark and of best in class quality.

13
Highlights

-Best in class Quality Assurance Department with standards and guidelines

followed of ISO 9001.

-Robust quality processes set-up at all the manufacturing plants within each
product department.

-Quality check within the stages of manufacturing resulting in less wastage of

materials and eco-friendly production.

-Wear and tear check of the manufacturing equipments, facilities and waste
management. Training to production employees. Cleaning as per validation
and master plan.

-Grievance and Complaint Handling.

-Process Documentation, Registration and Stability Maintenance Analysis

through flowcharts Finished product analysis.

The Quality Assurance Department Ensures:

-Knowledge sharing through product design documents and Lincoln research

center.

-Enhance the documents developed by the Quality Assurance division through

internal inspection and stage by stage approvals with proper validation.

-Develop product validation protocols, facilities scale up and timely approvals

of equipments, processes and products.

-Documentation controlling through accurate change procedures.

Assuring Quality of Products:

-cGMP Training.

14
-SOP Compliance.

-Release of batch for marketing.

-Line Clearance.

-Internal self inspection of the facility for compliance.

-Work-in-progress checks and effective sampling.

-Validation and Verification of records and documents.

-Complaint handling and Stability checks of products.

Quality Improvement Plans:

-360 degrees of feedback from the compliance and quality teams.

-Collating the feedback of consumers and product reviews.

-Annual check of the product quality and proposals for corrective measures.

-Analysis of the product changing trends, eco-friendliness and products.

-Strategy of product Manufacture.

Quality Certifications and Awards:

-ISO 9001:2015: Quality Management System.

-Quality Excellence Gold Award, IDMA (Indian Drug Manufacturer’s

Association).

-Gujarat State Export Awards in the year 1994-95.

-Udyog Ratan Award given by IES (Institute of Economic Studies) 1995-96.

-Niryat Ratan Award by IES (Institute of Economic Studies) 1995-96.

15
The manufacturing plant sprawls across in amiable surroundings of 30000 sq.
yard land with a garden offering optimal eco-friendly conditions. An individual
structure houses Administration, Quality Control Laboratory and Quality
Assurance section which spreads across 452 sq m. The units have always been
constructed with maximum attention and foresightedness through the design
stage to alleviate possibilities of cross contamination. For the convenience of
internal movement of resources – people and material, the manufacturing
facility corridor has been given a “U” shaped. Internal sectional corridors open
to the processing areas. Processing areas have been isolated from corridors by
ideal airlocks and pressure differentials. Similar kind of isolation and care exists
for preventing contamination for packaging also. Appropriate number of ideal
sized stores and quarantines are built to receive, quarantine and store a variety
of materials and finished products.

Since the initiation, Lincoln Pharmaceutical has always been giving vital drive
for establishing inspiring technology driven products striving for enhancing the
application of medications for improved therapeutic purposes.

The Research & Development center is furnished with state-of-the-art devices

and equipments for internal physical, chemical and microbiological analysis of
all products.

The Research & Development center is spearheaded by a cluster of specialized

technology evangelists. Activities like novel product development, quality
enhancement in existing products, process development and validation are
performed in this center.

The organization has always put in incessant efforts towards building products
through effective use of techniques like Optimized Drug Delivery – which
assures increased potency & efficiency, reduced side-effort & toxicity levels,

16
improved stability, decreased cost consequently increased availability ,
simplicity of administration and finest patient compliance.

With the enhanced patient consciousness & aggressive competition within the
makers prompts the organization to build & establish brilliance and originality
within its products.

The well-equipped Research & Development ideology of Lincoln has been

successful in bracing the winds of ever-changing pharmaceutical technology.
Due to the continual focused research, it has been possible for Lincoln to file a
patent for NAMSAFE – which is the hepato-protective combination of
Nimesulide with Recemethionine and a product patent for the protective
combination of nimsulide with racemethionine. Along with this, multiple
additional applications for patent are in the pipeline.

Understanding highest moral responsibilities, Lincoln Pharmaceutical’s R&D

center has pledged towards creating technology-based products at competitive
prices for the patients.

Production Department:

Tablet & Capsule Section

 A capacity of 100 crores tablets per annum / per single shift is offered by
the newly built-up facility.
 No B-Lactum, Hormone and Cancer Departments.
 Facilities to manufacture Sustained Release Formulation.
 Three exclusive granulation shops:
-Dry Granulation
-Wet Granulation

17
 -Colored Granulation
 Unidirectional flow of men and material.
 Six compression cubicles with separate Air Handling Units.
 Centralized Air condition System to maintain 40 RH and 22-Degree
Temperature in granulation, compression, blending and packing cubicles
areas.
 Flame proof motors in granulation and coating sections.
 All Non-Air Condition area fully ventilated with 5 micron filed air.
 Coating facility including 48″ – 150 kg NEOCOATER.
 Central Dust extraction system provided with pick up at all powder
generating point.
 Flame proof motors in granulation and coating sections.
 Water System: DM water having circulating loop to maintain 80-Degree
Celsius temperature. D.M. Storage tank of SS316.
 Own Deep Bore well for water.
 D G Set of 250 KWT.
 Stores are fully computerized.

Potential section

Sterile Liquid Injection Ampoules & Vials with capacity of 80,000 Ampoule per
shift & 25,000 Vials per shift (2ml to 50ml Vial). Sterile Area having pressure
gradient:

 15 Pascal in manufacturing and passage.

 25 Pascal in wash and sterile.
 40 Pascal in filling area.
 Multi column 80 per hour.
 Three Manufacturing rooms and Three separate filling areas.
 Sterile Dry Power B-Lactum 40,000 Vials per shift with Separate Entry &
AHU.
 Washing under HEPA filter.
 Sterilization by Double Door Dryer.
 Autoclave by Double Door Dryer.
 Poly Urethane coated jointless Flooring.
18
  Blister Packing of Ampoule and Vial.
 Shrink Package of finished products.

Liquid & Ointment Section

 4 Head filling, sealing and labeling line having 100 bottles per minute
capacity (40,000 Bottles per shift) total 2 lines.
 Manufacturing capacity of 3000 litres per day.
 Total area is ventilated with 5-micron air and filling areas are under
temperature control.
 Ointment manufacturing and packing: 20,000 Tubes per shift (15 gm).

Product list of Lincoln Pharmaceuticals:

o ALDASE
o ALPHANE
o ANTHEL-UP
o ANZYME
o ARH
o BTC-KIT
o CALBON-500
o CEFTALIN
o CEPY
o CHARG UP
o DERMOLIN
o DOMI-UP
o FETON SYP
o FULCAN
o HISTOLIN
o KODEX
o KONAZOL
o L-BEX
o NAMCOLD

19
o NAMSAFE
o NEPIN-SR
o PA12
o PENTALINK
o PROGUT
o PROLIN
o PROTOSOL
o R-PILL
o ROBILINK
o SALPHYLLIN-M
o SOLUDINE
o SPASLINK
o TOFLOX-OZ
o VIVIAN
o VIVIAN-GEL

20
 MARKETING DEPARTMENT

Marketing Departments of Lincoln Pharmaceuticals have a Specific brand for

their products in domestic market. Like:

Pharma

Holds this distinction of being the main division of Lincoln Pharmaceuticals

Limited showcasing the flagship brand of Nam Cold along with leading focus in
Anti Cold, Anti Biotic, Otolaryngology and Pain Management with a incredibly
diverse portfolio.

Lords

Lords Division primarily serves for Anti Malarial segment with leader brand
ARH.

Teresa

This department is entirely dedicated towards gynac products offering a

complete portfolio range of gynac medications. This department has more
than 30 brands in this segment.

The well known and bestseller product of Lincoln Pharmaceuticals are as

follows:

Nam-Cold : It was the first recognized brand of Lincoln , Nam Cold Tablet 10's is
a combination of respiratory medication used to treat common cold
symptoms, such as sneezing, runny nose, nasal and sinus congestion, stuffy
nose, or watery eyes. Nam Cold Tablet 10's consists of Nimesulide (pain killer),
Pseudoephedrine (decongestant), and Cetirizine (anti-allergic).

Prolin Vaginal Spray : Lincoln Pharmaceuticals launches Vaginal Spray for the
‘FIRST TIME IN INDIA ‘ Prolin Vaginal Spray is used to restore menstrual cycles
in women whose periods have stopped. It is a natural female hormone
important for regulating ovulation (release of an egg from a woman's ovary)

21
and menstruation. It is also used in the treatment of infertility to help you get
pregnant.

Tinnex : It is an amazing medication when it comes to treating Cochlear

Synaptic Tinnitus. Introduced by Lincoln Pharma with collaborating partner
Phafag (Switzerland), it has been manufactured under the licensing
arrangement & technical alliance.

Pa 12 Proglet: It is a 1000 mg Programmed Released Paracetamol. Pa 12

Proglets are developed to offer 12 hours of non-stop control of pain and fever.
Proglet Technology of Pa 12 Proglets guarantees the quantities of the
Paracetamol in the blood plasma are maintained for an extended period to
give better effectiveness as well as continuously healing action up to 12 Hours.
As a result additionally providing a benefit for the dosage convenience, 2
Proglets per day handle pain and fever for 24 Hours.

ARH1ml : A pioneering product of Lincoln Pharmaceuticals (LPL), “ARH 1”, the

Anti-malarial Drug has been formulated and introduced utilizing advanced
technology recognized as Dose Optimization Technology according to the
Novel Drug Delivery System (NDDS). Whilst principal treatment plan for
malaria is complicated and difficult to administer, ARH 1 is straightforward and
highly effective which in turn makes it convenient for malarial patients to
endure and recover out of this disease.

Lincoln Pharmaceuticals Limited has to its name, 4 approved patents in vital

divisions:

 Patent no. IN224188 Pharmaceutical Composition containing Anti-

inflammatory and Decongestant (sustained release) for treating Allergic
Rhinitis.
 Patent no. IN209056 is a Nasal Drug delivery system of Ondansetron
Hydrochloride and Process for Preparation Thereo.
 Patent no. IN209039 is a Mouth Melting Pharmaceutical dosage film
comprising medicaments and process for Preparation of Thereof.

22
  Patent no. IN214054 is a Pharmaceutical Composition Comprising
MISOPROSTOL for Vaginal Suppository dosage form and process for
Preparation Thereo.

Lincoln Pharmaceuticals have a well – connected distribution network, in all

zones – North, South, East and West of India. The dominant Indian supplying
cities are Jammu, Chandigarh, Ultranchal, Ambala, Delhi, Ghaziabad,Guwaha,
Patna, Lucknow, Jaipur, Ranchi, Patna, Kolkata, Cuttak, Raipur, Nagpur, Indore,
Vijaywada, Chennai, Banglore and Ahmedabad.

The presence of Lincoln Pharmaceuticals etched out in various countries like

Benin, Bhutan, Bolivia, Botswana, Cameroon,Chile, Combodia, Congo, Costa
Rice, El-Salvador, Ethiopia, Fiji, Ghana, Guatemala, Guyana, Honduras, Hong
Kong, Jamaica, Kenya, Lebanon, Madagascar, Malawi, Mozambique, Myanmar,
Nepal, Nigeria, Panama, Peru, Philippinies, Rwanda, Senegal, Sri Lanka,
Tanzania, Thailand, Trinidad & Tobago, Uganda, Vietnam, Zambia, Zanzibar and
Zinbabwe. The company had a trade agreement with foreign countries.

23
 FINANCING DEPARTMENT

Mr. Bhavin Patel is an Executive Finance of Lincoln Pharmaceuticals ltd. Mr.

Pratik Shah is a Chief Financial Officer of a Company.

The Highlights of the company’s performance for the year ended March
31,2021 are as under:

During the year under review, the Company achieved revenue of ₹ 4,464.04
Lakhs as against ₹ 4,435.23 Lakhs in the previous year. The Profit after Tax of
the Company is ₹ 184.39 Lakhs as against profit after tax of ₹ 191.33 Lakhs in
previous year.

The Company continues with its rigorous cost- optimization initiatives and
efficiency improvements, which have resulted in significant savings through
continued focus on cost controls, process efficiencies and product/formulation
innovations that exceed ultimate consumer expectations in all areas, enabling
the Company to maintain profitable growth in the a healthy economic
scenario.

During the year under review, the Company has not altered / modified the
authorised share capital of the Company. The paid-up share capital of the
company as on March 31, 2021 was ₹ 10,00,00,000/- divided into 1,00,00,000
equity shares of ₹ 10/- each fully paid up and there has been no change in the
capital structure of the Company.

The Net Revenue has gone up from Rs. 397.5 crores in FY20 to Rs.429 crores in
FY21, a rise of 8.1% . On the other hand, the EBITDA for FY21 is Rs. 92.8 crores,
a growth of 21.1% from Rs. 76.6 crores in FY20. The Profit After Tax (PAT) for
24
FY21 stands at Rs. 62.2 crores, an increase of 21% from Rs. 51.4 crores in FY20.
The exports for FY21 has rise by 18.4% to Rs. 270 crores.

At the end of FY21, Lincoln Pharmaceuticals Limited stands debt-free with a

strong liquidity position. In the last five years, the Company has delivered a
staggering 20 % CAGR in profits. At current pace, Lincoln Pharmaceuticals
Limited will easily surpass the industry growth levels and reach double digit
sales growth with better margins.

The Company has taken adequate insurance to cover the risks to its
employees, property (land and buildings), plant, equipment and other assets.

The Company reports 9.83% rise in the revenue from operations of Rs.
41,305.52 Lakhs (Domestic ₹ 15,568.29 Lakhs and Exports ₹ 25,737.23 Lakhs)
as against ₹ 37,608.83 Lakhs (Domestic ₹ 15,908.41 Lakhs and Exports ₹
21,700.42 Lakhs) in the previous year. EBITDA for the year was ₹ 8,811.61
Lakhs (increase 23.24%) as against ₹ 7,149.96 Lakhs in the previous year. The
profit after tax has increased to ₹ 6,040.61 Lakhs on a standalone basis as
against profit after tax of ₹ 4,956.36 Lakhs in previous year representing
growth rate of 21.88% during the financial year ended March 31, 2021. EPS for
the year was ₹ 30.20 (increase 21.88%) per share as compared to ₹ 24.78 in
the previous year. Detailed working on operation ofhe Company as provided in
the management discussion and analysis report as forms part of these Annual
Report.

The Company has an uninterrupted dividend payment history and considering

the financial performance for the financial year ended March 31, 2021, The
Board of Directors has recommended a dividend of Rs. 1.50/- (Rupees one and
fifty paise only) per equity share of face value of 10/- each (i.e. 15%) for the
financial year ended March 31, 2021. Dividend is subject to approval of
members at the ensuing annual general meeting (“AGM) and shall be subject

25
to deduction of income tax at source. Regulation 43A of the SEBI Listing
Regulations as amended by the SEBI [(Listing Obligations and Disclosure
Requirements) (Second Amendment) Regulations, 2016, makes it mandatory
for the top one thousand listed entities based on market capitalization
(calculated as on March 31 of immediate previous financial year)] shall
formulate a dividend distribution policy. In compliance with the provisions of
Regulation 43A of the SEBI Listing Regulations, the Board of Directors of the
Company at its meeting held on May 25,2021, has approved and adopted the
dividend distribution policy of the Company. The policy inter alia, lays down
various parameters relating to declaration / recommendation of dividend.

During the year under review, the company has transferred a sum of ₹ 50.00
Lakhs to the general reserve out of the amount available for appropriation for
the financial year ended March 31, 2021 (Previous Year transferred a sum of ₹
50.00 Lakhs was transferred to general reserve).

Ratios of Lincoln Pharmaceuticals Ltd. of year 2020-21:-

Profitability Ratios:

1. Operating Profit Margin = 20.55%

2. Net Profit Margin = 14.68%
3. Return on Net Worth = 16.57%

Working Capital Ratio:

1. Debtors Turnover [Days] = 96 Days

2. Inventory Turnover [Days] = 86 days

Gearing Ratios:

1. Interest Coverage = 59.44 Times

26
2. Debt/Equity = Nil
3. Liquidity Ratios:
1. Current Ratio = 4.17 : 1

27
 CORPORATE SOCIAL RESPONSIBILITY

Business is the limb of the society and being in the business of healthcare it is
out moral duty to give back to the society. Corporate Social Responsibility is a
part of business strategy and to make sure that they add newer initiatives
every year and reach out to more individuals of the society and improve the
overall health standards of the society.

They believe in investing their time and money for the betterment of the
society. They have gone the extra mile to prevent global warming and come up
with innovative healthcare solutions at affordable rates.

Lincoln Pharmaceuticals Limited has always been dedicated to playing a role in

uplifting the society and ensuring a brighter future. Part of the Company’s
values are to be actively involved in philanthropic and motivational activities
which set a good example. The Company is always extending its support to
various humanitarian causes and making a positive impact.

To support the specially-abled, we joined hands with Blind People’s Association

and extended financial help. For supporting the educational aspirations of
numerous students, we partnered with Dr. Jit Mehta Balshala Trust, Kadi
Taluka Public Charitable Trust, Shree Shertha Kelvani Mandal and Shri Sarswati
Kanya Kelavani Mandal.

As an initiative against hunger and to ensure better healthcare for the needy,
we provided help to Sardardham, Shardaben Gulabdas Patel Public Charity
Trust, Shree Someshwara Ashram Trust, Shri Brahm Samaj Seva Trust, Shri
Gramy Seva Sangthan, Shri Kadi Ru Mahajan Pathikashram, Sri Sathya Sai Heart
Hospital and The Akshaya Patra Foundation. To provide better medical services
to the slum dwellers, we extended help to the Smile Foundation.
28
The CSR activities of Lincoln Pharmaceuticals Limited are continuously helping
the needful and our partnership with various NGOs and trusts have led to
fruitful initiatives. Moving forward we will continue to build on our good work
and create a society which welcomes and nurtures all.

Lincoln’s mission

Quality of healthcare in the country is a major encumbrance and they want to

ensure that through their Corporate Social Responsibility activities we make
the difference at a huge scale. They want to make healthcare more accessible
to the common people. As a gesture, they also want to reach out to rural
masses and provide them medicines free of cost.

They are not only committed in providing healthcare at affordable rates for
certain community, but also make the planet more sustainable by making the
quality of life of our upcoming generation better, especially with healthcare.

Initiatives

Being the leaders in healthcare domain, Lincoln Pharma has eventually

developed new initiatives to reach out to communities and contribute towards
the overall growth of people, economy, planet, etc. Their initiatives to reach
out to society include volunteering by employees, providing right medicines at
villages, bringing the quality of hygiene education in masses, etc.

They have envisioned integrating social and environmental concerns to our

daily business operations and undertaking more initiatives in the times to
come.
29
Corporate Social Responsibility reflects the strong commitment of the
Company to improve the quality of life of the workforce and their families and
also the community and society at large. The Company believes in undertaking
business in a way that will lead to overall development of all stakeholders and
society.

The Company has continued on spending in projects like Eradicating Hunger,

Preventive Healthcare, Women Empowerment, Girls Education, etc. which is in
accordance with the provisions of Schedule VII of the Act and the CSR Policy of
the Company.The report on Corporate Social Responsibility Activities along
with the annexure as per the Rule (8) of The Companies (Corporate Social
Responsibility policies) Rules 2014 is annexed to this Board’s Report.

The Company has its CSR Policy within broad scope laid down in Schedule VII
to the Act, as projects/programs/activities, excluding activities in its normal
course of business. The policy is duly approved by the Board of Directors.

1. A brief outline of the Company’s CSR policy, including overview of projects

or programs proposed to be undertaken and a reference to the web-link to the
CSR policy and projects or programs:

I. Promoting education, health care, eradicating hunger and malnutrition and

Reducing inequalities by promoting Gender Equality

II. Rural development projects.

2. Composition of the CSR Committee:

As on the date of this report, CSR Committee consists of 3 (three) Directors as

its Members with one Independent Director in the Committee.

a) Mr Ishwarlal A. Patel - Member (Independent Director)

30
b) Mr Mahendra G. Patel - Member

c) Mr Munjal M. Patel - Member

3. Average net profit of the Company for last three financial years:

Average Net Profit: 4,608.22 Lakhs

4. Prescribed CSR Expenditure (Two Percent of the amount as in item 3 above):

Company is required to spend 92.16 Lakhs towards CSR.

Over the past decade, the company has focused on several corporate social
responsibility programs to drive positive and sustainable change in building
resilient communities. During the year, the Company spent ₹ 1.11 crores
(Rupees one crore eleven lakhs) on Corporate Social Responsibility activities.
Corporate Social Responsibility reflects the strong commitment of the
Company to improve the quality of life of the workforce and their families and
also the community and society at large. The Company believes in undertaking
business in a way that will lead to overall development of all stakeholders and
society. Further, the Company has continued on spending in projects like
eradicating hunger, preventive healthcare, women empowerment, girls
education, etc. which is in accordance with the provisions of Schedule VII of
the Act and the Corporate Social Responsibility Policy of the Company.

In accordance with Section 135 of the Act and Rule 8 of the Companies
(Corporate Social Responsibility Policy) Rules, 2014 the report on CSR activities
along with its annexure as forms part of this directors’ report.

The Company works actively to enhance the employability of youth in the

nearby locations wherever it operates, leading to income generation and
economic empowerment in the marginalized sections of the communities. The
31
Company’s Corporate Social Responsibility (CSR) policy intends to focus on
certain initiatives, inter alia, in the fields of promoting education, health care,
eradicating hunger and malnutrition and reducing inequalities by promoting
Gender Equality.

In line with the provisions of Section 135 of the Act, read with Schedule VII of
the Act, the board has constituted the CSR committee for the purpose of
determining the activities to be undertaken by the Company towards the CSR.

Brief description and terms of reference: The terms of reference of CSR

articulates the roles, responsibilities and powers of the CSR under Section 135
read with Schedule VII of the Act, besides other terms as may be referred to by
the board of directors from time to time.

32
 PORTER’S FIVE FORCE ANALYSIS

Lincoln Pharmaceuticals Ltd (India) can use Porter Five Forces as a strategic
management tool to do industry analysis . It will help Leaders at Lincoln
Pharmaceuticals Ltd in mapping the various competitive forces that are
prevalent in Healthcare industry in both local markets and international
markets.

The Porter Five Forces that determine the industry structure in Biotechnology
& Drugs are -

1. Bargaining power of suppliers in Biotechnology & Drugs :

If suppliers have strong bargaining power then they will extract higher
price from the Lincoln Pharmaceuticals Ltd. It will impact the potential of
Lincoln Pharmaceuticals Ltd to maintain above average profits in
Biotechnology & Drugs industry. Sun pharma and lupin have a large
power of suppliers for their tablet dosage.

2. Bargaining power of buyers of Lincoln Pharmaceuticals Ltd and

Healthcare sector :
If the buyers have strong bargaining power then they usually tend to
drive price down thus limiting the potential of the Lincoln
Pharmaceuticals Ltd to earn sustainable profits. Cipla and Zydus are the
well known company of pharmaceuticals which have a power of buyers
from the very long runs .

3. Threat of new entrants in Biotechnology & Drugs industry :

If there is strong threat of new entrants in the Biotechnology & Drugs
industry then current players will be willing to earn lower profits to
reduce the threats from new players. Pharmaceuticals industry is
33
 currently having no new competition threat from the Indian as well as
global market but if the new competitors arise then the company like
Lincoln pharma may suffers.

4. Threat of substitute products and services in Biotechnology & Drugs

sector :
If the threat of substitute is high then Lincoln Pharmaceuticals Ltd has to
either continuously invest into Research and development or it risks
losing out to disruptors in the industry. There are hundreds of substitute
of the original product big companies like Sun, Luoin,Cipla and etc. have
a large force of research and development for copying the new product
line or any new variant of the product which the company launch.

5. Rivalry among existing players in Biotechnology & Drugs industry :

If competition is intense then it becomes difficult for existing players
such as Lincoln Pharmaceuticals Ltd to earn sustainable profits. Lincoln is
currently ranked in the top 100 Pharmaceuticals Industry of India, which
clearly shows the Competiton of the domestic sector.

Zydus Pharmaceuticals have a large range of products and the company is

always in the Launching of the new product which shows the strong Research
and development department that the company holds. Zydus is also
considered as a hero of Pharmaceuticals because of its Remdsivir, used to treat
patients suffering from Covid-19 .

34
 COMPETITION ANALYSIS

It is often argued that India‘s drug market is a competitive one with nearly
20,000 companies competing in various therapeutic segments. This is said to
have kept the drug price at low level. However, it is a highly contestable claim
as evidence suggests that despite being highly fragmented, there is high
market concentration in these markets. Around 250-300 companies control
70% of the total market share.

Key Players that enjoy a dominant position in the Indian pharmaceutical

industry are Sun Pharmaceuticals ,Cipla Pharmaceutical , Lupin
pharmaceuticals, Dr. Reddy’s Pharmaceuticals, Aurobindo Pharmaceuticals,
Zydus Pharmaceuticals, Glenmark Pharmaceuticals and many other potential
players are the well known players of Indian Pharmaceuticals Companies of
India.

Sun Pharmaceuticals is the largest pharmaceutical company from India and the
fifth largest specialty generic company in the world.In FY19, US formulations
contributed the most to company’s sales with 37%, followed by India branded
formulations at 26%. It serves over 150 markets across the world , they have
more than 2,000 marketed products and more than 40 manufacturing sites. In
FY21, the company’s total income reached US$ 4.5 billion, Gross sales for Q1
FY22 stood at Rs. 96,694 million (US$ 1.31 billion), up 29% YoY. Net Profit for
the year FY20 was Rs. 37,649 million. Its Market Capital as per January 2022 ₹
198,484 crore (US$26 billion).

Cipla is a leading pharmaceutical from India with presence across the world. It
was established in 1935 as Chemical Industrial & Pharmaceutical Laboratories
Ltd and changed to its current name in 1984. The company has a vast portfolio
with more than 1,500 products in the market. Over 43 state-of-the-art
manufacturing facilities for API and formulations. Ranked amongst the top 10
35
most dispensed generic companies in North America.The company’s business
is divided into three strategic units - APIs, respiratory and Cipla Global Access.
Its largest market is India, followed by Africa and North America.

The company’s total revenue reached Rs. 19,160 crore (US$ 2.60 billion) in
FY21. Net Profit for the year FY21 was Rs. 2,140. 10 crores. Its Market Capital
as per January 2022 ₹ 75,206 crore (US$10 billion).

Lupin Ltd. is a leading pharmaceutical company from India and is amongst the
top 10 generic companies in the world. It started its business in 1968 and over
the years has become one of the largest pharmaceutical companies in India
and the world.

In FY21, Lupin’s total sales stood at Rs. 149,270 million. It has 18

manufacturing sites and its products sold in more than 100 countries. Its
consolidated income stood at Rs. 16,751 million (US$ 227.45 million) in FY21.
Its Market Capital as per January 2022 ₹ 40,894 crore (US$5.4 billion).

Sun has capabilities across dosage forms like injectables, sprays, ointments,
creams, liquids, tablets, and capsules. Sun pharmaceutical product portfolio
includes generics, branded generics, speciality, difficult-to-make technology
intensive products, over-the-counter (OTC), anti-retrovirals (ARVs), Active
Pharmaceutical Ingredients (APIs) and intermediates.

Lupin pharmaceuticals has a range of products in both branded and generic

formulations, biotech products, Active Pharmaceutical Ingredients (API) and
speciality drugs to address evolving patient needs.

36
Lincoln Pharmaceuticals are engaged in producing tablets, capsule, liquid
injection and sprays. The company is facing major competiton from the
industry with the substitute products they produce . Still Lincoln products are
differentiated because of the quality they had for there products.

37
 SWOT ANALYSIS

SWOT Analysis is a methodological approach to analyze the - Strengths &

Weaknesses that Lincoln Pharmaceuticals Ltd possess, and Opportunities &
Threats that the company faces because of competitive and macro-economic
factors prevalent in India.

Strengths :-

1. Track record of innovation:

Even though most players in the Healthcare strive to innovate, Lincoln
Pharmaceuticals Ltd has successful record at consumer driven
innovation.

2. First mover advantage:

In the increasingly crowded market place. The new products are rapidly
increasing Lincoln Pharmaceuticals Ltd market share in the
Biotechnology & Drugs industry.

3. Wide geographic presence :

Lincoln Pharmaceuticals Ltd has extensive dealer network and associates
network that not only help in delivering efficient services to the
customers but also help in managing competitive challenges in
Biotechnology & Drugs industry.

4. Talent management :

38
 At Lincoln Pharmaceuticals Ltd and skill development of the employees -
Human resources are integral to the success of Lincoln Pharmaceuticals
Ltd in Biotechnology & Drugs industry.

5. High margins :
Compare to Biotechnology & Drugs industry's competitors - Even though
Lincoln Pharmaceuticals Ltd is facing downward pressure on profitability,
compare to competitors it is still racking in higher profit margins.

6. Strong brand recognition:

Lincoln Pharmaceuticals Ltd products have strong brand recognition in
the Biotechnology & Drugs industry. This has enabled the company to
charge a premium compare to its competitors in Biotechnology & Drugs
industry.

Weaknesses :-

1. Low investments into Lincoln Pharmaceuticals Ltd's customer oriented

services :
This can lead to competitors gaining advantage in near future. Lincoln
Pharmaceuticals Ltd needs to increase investment into research and
development especially in customer services oriented applications.

2. High turnover of employees :

Higher turnover of employees at the lower levels is also a concern for
the Lincoln Pharmaceuticals Ltd . It can lead to higher salaries to
maintain the talent within the firm.

3. High cost of replacing existing experts :

39
 High cost of replcing existing experts within the Lincoln Pharmaceuticals
Ltd. Few employees are responsible for the Lincoln Pharmaceuticals Ltd's
knowledge base and replacing them will be extremely difficult in the
present conditions.
4. Business Model :
The business model of Lincoln Pharmaceuticals Ltd can be easily imitated
by the competitors in the Biotechnology & Drugs industry. To overcome
these challenges company name needs to build a platform model that
can integrate suppliers, vendors and end users.

5. Gross Margins and Operating Margins :

Gross Margins and Operating Margins which could be improved and
going forward may put pressure on the Lincoln Pharmaceuticals Ltd
financial statement.

6. Declining Revenue :
Declining per unit revenue for Lincoln Pharmaceuticals Ltd
competitiveness in the Biotechnology & Drugs industry is putting
downward pressure on the profitability. A starting guide to manage this
situation for companyname is objectively assessing the present value
propositions of the various products.

Opportunities :-

1. Technologicl Innovtion :
Accelerated technological innovations and advances are improving
industrial productivity, allowing suppliers to manufacture vast array of
products and services. This can help Lincoln Pharmaceuticals Ltd to
significantly venture into adjacent products.

2. Trend of customers migrating to higher end products :

40
 It represents great opportunity for Lincoln Pharmaceuticals Ltd, as the
firm has strong brand recognition in the premium segment, customers
have experience with excellent customer services provided by Lincoln
Pharmaceuticals Ltd brands in the lower segment. It can be a win-win for
the company and provides an opportunity to increase the profitability.

3. Increasing customer base in lower segments :

As customers have to migrate from un-organized operators in the
Healthcare industry to licensed players. It will provide Lincoln
Pharmaceuticals Ltd an opportunity to penetrate entry level market with
a no-frill offering.

4. Customer preferences are fast changing :

Driven by rising disposable incomes, easy access to information, and fast
adoption of technological products, customers today are more willing to
experiment / try new products in the market. Lincoln Pharmaceuticals
Ltd has to carefully monitor not only wider trends within the
Biotechnology & Drugs industry but also in the wider Healthcare sector.

5. Low cost for New Product :

Lowering of the cost of new product launches through third party retail
partners and dedicated social network. Lincoln Pharmaceuticals Ltd can
use the emerging trend to start small before scaling up after initial
success of a new product.

6. Rapid Expansion of Economy :

As the US economy is improving faster than any other developed
economy, it will provide Lincoln Pharmaceuticals Ltd an opportunity to
expand into the US market. Lincoln Pharmaceuticals Ltd already have
know-how to operate into the competitive US market.

Threats :-
41
1. Changing political environment :
Changing political environment with US and China trade war, Brexit
impacting European Union, and overall instability in the middle east can
impact Lincoln Pharmaceuticals Ltd business both in local market and in
international market.

2. Competitive pressures :
As the new product launch cycles are reducing in the Healthcare
industry. It has put additional competitive pressures on players such as
Lincoln Pharmaceuticals Ltd. Given the large customer base, Lincoln
Pharmaceuticals Ltd can't respond quickly to the needs of the niche
markets that disruptors are focusing on.

3. Distrust of institutions :
Distrust of institutions and increasing threat of legal actions for Lincoln
Pharmaceuticals Ltd - As the WTO regulations and laws are difficult to
enforce in various markets. Legal procedures have become expensive
and long drawn process. It can lead to less investment into emerging
markets by Lincoln Pharmaceuticals Ltd thus resulting in slower growth.

4. Changing demographics :
As the babyboomers are retiring and new generation finding hard to
replace their purchasing power. This can lead to higher profits in the
short run for Lincoln Pharmaceuticals Ltd but reducing margins over the
long run as young people are less brand loyal and more open to
experimentation.

5. Shortage of skilled human resources :

42
 Given the high turnover of employees and increasing dependence on
innovative solution, companyname can face skilled human resources
challenges in the near future.

6. Commoditization of the product segment :

The biggest challenge for Lincoln Pharmaceuticals Ltd and other players
in the industry is the increasing commoditization of the products in
Healthcare industry.

43
 SUGGESTIONS

The competition in Pharmaceutical sector is challenging for the Company and

for defeating the competition the company should more focus on the Product ,
by Product it means the Quality and Branding of the product which plays the
vital role in Marketing of the product.

Speaking about the company decilining share revenue in the current market is
a serious matter of concern. For attracting the investors the company should
Lower its per share pricing for the short run and more emphasis should be
given to the market volatility.

The new generation Buyers are not brand loyal and always opt to discover new
product which can be an advantage for the company. If the company starts
branding and advertising its product at the potential buyers market like Onile
Market, it may end up making its new and impulsive customers into potential /
brand loyal customers.

Currently the company is enjoying the profitability from the product from high
profit margin by competing its competitors but for enjoying this profitability
for the long run the company should more focus on the pricing and profitability
of the product. Drug industry faces the extreme pressurize condition and for
making your suppliers stick to you company whould lower its suppliers cost of
margin.

Research and development is the main player for the company for that
company should invest more on the research and development department of
the new product for the betterment of the society and better standards of
living.

44
Gross Margins and Operating Margins is pressurized for the financial statement
of the Lincoln pharmaceuticals ltd. Company should control its operating
expense which will lead to increase in the profitability and also they can
control their production cost by using new technology .

The company should hire Experts for the improvement of the company
performing and addressing the weakness of the company into its strength.
Experts increase the company performance and direct the company into right
path.

Company should also focus on the current business model of the company,
they should find the best suitable Business Model to compete in Market.

Company should now enter into the Online Selling platform like, TATAmg,
PharmEasy, Apollo Pharmacy, Netmeds, Medplusmart and etc.

45
 BIBLIOGRAPHY
Sources of Information:-

www.lincolnpharma.com

www.goodreturns.in

Document of Lincoln Pharmaceuticals :-

27th Annual Report of 2020-21

26th Annual Report of 2019-20

Corporte Socil Responsibility policy

Special Thanks to Mr. Nikham Sir and Miss Neha Mam from Human Resource
Department of and Mr. Sandip from Product Management Department of
Lincoln Pharmaceuticals for their precious and valuable time and for
enlightening me.

46